Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    Palovarotene

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Quotient Sciences Extends Mfg Partnership For Ultra-Rare Disease
    Quotient Sciences Extends Mfg Partnership For Ultra-Rare Disease

    27 Feb 2026

    // PRESS RELEASE

    https://www.quotientsciences.com/news/quotient-sciences-extends-commercial-manufacturing-partnership-ultra-rare-disease-treatment

    PRESS RELEASE
    27 Feb 2026
    Share Share
    US FDA approves French drugmaker Ipsen's rare bone disorder drug
    US FDA approves French drugmaker Ipsen's rare bone disorder drug

    17 Aug 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-ipsens-rare-bone-disorder-drug-2023-08-16/

    REUTERS
    17 Aug 2023
    Share Share
    Ipsen says EC rejects marketing authorization for bone disorder drug
    Ipsen says EC rejects marketing authorization for bone disorder drug

    19 Jul 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/ipsen-says-european-commission-rejects-marketing-authorization-bone-disorder-2023-07-19/

    REUTERS
    19 Jul 2023
    Share Share
    FDA adcomm votes in favor of Ipsen's fibrodysplasia drug
    FDA adcomm votes in favor of Ipsen's fibrodysplasia drug

    29 Jun 2023

    // Katherine Lewin ENDPTS

    https://endpts.com/fda-adcomm-votes-in-favor-of-ipsens-fibrodysplasia-drug/

    Katherine Lewin ENDPTS
    29 Jun 2023
    Share Share
    Ipsen announces +ve outcome of FDA Advisory Committee on investig. palovarotene
    Ipsen announces +ve outcome of FDA Advisory Committee on investig. palovarotene

    28 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/29/2696672/0/en/Ipsen-announces-positive-outcome-of-FDA-Advisory-Committee-on-investigational-palovarotene-for-fibrodysplasia-ossificans-progressiva.html

    GLOBENEWSWIRE
    28 Jun 2023
    Share Share
    FDA reviewers on Ipsen's potential ultra-rare disease drug
    FDA reviewers on Ipsen's potential ultra-rare disease drug

    27 Jun 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/fda-reviewers-on-ipsens-potential-fibrodysplasia-drug-post-hoc-analysis-may-be-enough/

    Zachary Brennan ENDPTS
    27 Jun 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.